Potential Role of IFNγ Inhibition in Refractory Cytokine Release Syndrome Associated with CAR T-cell Therapy
Here we review the pathophysiology and management of cytokine release syndrome (CRS) secondary to immunotherapy, and potential options for CRS refractory to IL6 inhibition and glucocorticoids, for which there are no proven treatments. To illustrate, we describe a patient with B-cell acute lymphoblas...
Gespeichert in:
| Veröffentlicht in: | Blood cancer discovery 2022-03, Vol.3 (2), p.90-94 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 94 |
|---|---|
| container_issue | 2 |
| container_start_page | 90 |
| container_title | Blood cancer discovery |
| container_volume | 3 |
| creator | McNerney, Kevin O DiNofia, Amanda M Teachey, David T Grupp, Stephan A Maude, Shannon L |
| description | Here we review the pathophysiology and management of cytokine release syndrome (CRS) secondary to immunotherapy, and potential options for CRS refractory to IL6 inhibition and glucocorticoids, for which there are no proven treatments. To illustrate, we describe a patient with B-cell acute lymphoblastic leukemia who developed refractory grade 4 CRS following CD19-directed chimeric antigen receptor T-cell therapy, treated with tocilizumab, methylprednisolone, siltuximab, and the IFNγ inhibitor emapalumab, with complete remission from leukemia for 12 months. See related article by Bailey et al., p. 136 (15). |
| doi_str_mv | 10.1158/2643-3230.BCD-21-0203 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9245357</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2619208974</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2926-521385280f83b4fa8cfcdabf5da91704e06fbdad99cc48dd3f47e1e78deb456c3</originalsourceid><addsrcrecordid>eNpVkdtu1DAQhi0EolXpI4B8yU2Kj4lzg7QECitVtFqWa8uxx6whiRc72yrPxXvwTCTqsoKrGc3hn_n1IfSSkitKpXrDSsELzji5ete8LxgtCCP8CTo_1kX99JRzcoYuc_5OCGGc8orz5-iMS0Jlqapz1N_FEYYxmA5vYgc4ery-_vz7F14Pu9CGMcQBhwFvwCdjx5gm3Exj_BEGmGsdmAz4yzS4FHvAq5yjDWYEhx_CuMPNaoO3hYWuw9sdJLOfXqBn3nQZLo_xAn29_rBtPhU3tx_XzeqmsKxmZSEZ5UoyRbzirfBGWW-dab10pqYVEUBK3zrj6tpaoZzjXlRAoVIOWiFLyy_Q20fd_aHtwdnZYTKd3qfQmzTpaIL-vzOEnf4W73XNhOSymgVeHwVS_HmAPOo-5MWJGSAesmYlrRlRdSXmUfk4alPMOYE_naFEL7T0QkIvJPRMSzOqF1rz3qt_fzxt_WXD_wDipJLo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2619208974</pqid></control><display><type>article</type><title>Potential Role of IFNγ Inhibition in Refractory Cytokine Release Syndrome Associated with CAR T-cell Therapy</title><source>MEDLINE</source><source>PubMed Central</source><creator>McNerney, Kevin O ; DiNofia, Amanda M ; Teachey, David T ; Grupp, Stephan A ; Maude, Shannon L</creator><creatorcontrib>McNerney, Kevin O ; DiNofia, Amanda M ; Teachey, David T ; Grupp, Stephan A ; Maude, Shannon L</creatorcontrib><description>Here we review the pathophysiology and management of cytokine release syndrome (CRS) secondary to immunotherapy, and potential options for CRS refractory to IL6 inhibition and glucocorticoids, for which there are no proven treatments. To illustrate, we describe a patient with B-cell acute lymphoblastic leukemia who developed refractory grade 4 CRS following CD19-directed chimeric antigen receptor T-cell therapy, treated with tocilizumab, methylprednisolone, siltuximab, and the IFNγ inhibitor emapalumab, with complete remission from leukemia for 12 months. See related article by Bailey et al., p. 136 (15).</description><identifier>ISSN: 2643-3230</identifier><identifier>EISSN: 2643-3249</identifier><identifier>DOI: 10.1158/2643-3230.BCD-21-0203</identifier><identifier>PMID: 35015687</identifier><language>eng</language><publisher>United States: American Association for Cancer Research</publisher><subject>Cytokine Release Syndrome - drug therapy ; Hematologic Neoplasms ; Humans ; Immunotherapy, Adoptive - adverse effects ; In Focus ; Interferon-gamma ; Macrophage Activation ; Receptors, Chimeric Antigen - immunology ; T-Lymphocytes</subject><ispartof>Blood cancer discovery, 2022-03, Vol.3 (2), p.90-94</ispartof><rights>2021 American Association for Cancer Research.</rights><rights>2021 American Association for Cancer Research 2021 American Association for Cancer Research</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2926-521385280f83b4fa8cfcdabf5da91704e06fbdad99cc48dd3f47e1e78deb456c3</citedby><cites>FETCH-LOGICAL-c2926-521385280f83b4fa8cfcdabf5da91704e06fbdad99cc48dd3f47e1e78deb456c3</cites><orcidid>0000-0002-4359-3569 ; 0000-0002-8321-0403</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245357/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245357/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35015687$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>McNerney, Kevin O</creatorcontrib><creatorcontrib>DiNofia, Amanda M</creatorcontrib><creatorcontrib>Teachey, David T</creatorcontrib><creatorcontrib>Grupp, Stephan A</creatorcontrib><creatorcontrib>Maude, Shannon L</creatorcontrib><title>Potential Role of IFNγ Inhibition in Refractory Cytokine Release Syndrome Associated with CAR T-cell Therapy</title><title>Blood cancer discovery</title><addtitle>Blood Cancer Discov</addtitle><description>Here we review the pathophysiology and management of cytokine release syndrome (CRS) secondary to immunotherapy, and potential options for CRS refractory to IL6 inhibition and glucocorticoids, for which there are no proven treatments. To illustrate, we describe a patient with B-cell acute lymphoblastic leukemia who developed refractory grade 4 CRS following CD19-directed chimeric antigen receptor T-cell therapy, treated with tocilizumab, methylprednisolone, siltuximab, and the IFNγ inhibitor emapalumab, with complete remission from leukemia for 12 months. See related article by Bailey et al., p. 136 (15).</description><subject>Cytokine Release Syndrome - drug therapy</subject><subject>Hematologic Neoplasms</subject><subject>Humans</subject><subject>Immunotherapy, Adoptive - adverse effects</subject><subject>In Focus</subject><subject>Interferon-gamma</subject><subject>Macrophage Activation</subject><subject>Receptors, Chimeric Antigen - immunology</subject><subject>T-Lymphocytes</subject><issn>2643-3230</issn><issn>2643-3249</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkdtu1DAQhi0EolXpI4B8yU2Kj4lzg7QECitVtFqWa8uxx6whiRc72yrPxXvwTCTqsoKrGc3hn_n1IfSSkitKpXrDSsELzji5ete8LxgtCCP8CTo_1kX99JRzcoYuc_5OCGGc8orz5-iMS0Jlqapz1N_FEYYxmA5vYgc4ery-_vz7F14Pu9CGMcQBhwFvwCdjx5gm3Exj_BEGmGsdmAz4yzS4FHvAq5yjDWYEhx_CuMPNaoO3hYWuw9sdJLOfXqBn3nQZLo_xAn29_rBtPhU3tx_XzeqmsKxmZSEZ5UoyRbzirfBGWW-dab10pqYVEUBK3zrj6tpaoZzjXlRAoVIOWiFLyy_Q20fd_aHtwdnZYTKd3qfQmzTpaIL-vzOEnf4W73XNhOSymgVeHwVS_HmAPOo-5MWJGSAesmYlrRlRdSXmUfk4alPMOYE_naFEL7T0QkIvJPRMSzOqF1rz3qt_fzxt_WXD_wDipJLo</recordid><startdate>20220301</startdate><enddate>20220301</enddate><creator>McNerney, Kevin O</creator><creator>DiNofia, Amanda M</creator><creator>Teachey, David T</creator><creator>Grupp, Stephan A</creator><creator>Maude, Shannon L</creator><general>American Association for Cancer Research</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-4359-3569</orcidid><orcidid>https://orcid.org/0000-0002-8321-0403</orcidid></search><sort><creationdate>20220301</creationdate><title>Potential Role of IFNγ Inhibition in Refractory Cytokine Release Syndrome Associated with CAR T-cell Therapy</title><author>McNerney, Kevin O ; DiNofia, Amanda M ; Teachey, David T ; Grupp, Stephan A ; Maude, Shannon L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2926-521385280f83b4fa8cfcdabf5da91704e06fbdad99cc48dd3f47e1e78deb456c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Cytokine Release Syndrome - drug therapy</topic><topic>Hematologic Neoplasms</topic><topic>Humans</topic><topic>Immunotherapy, Adoptive - adverse effects</topic><topic>In Focus</topic><topic>Interferon-gamma</topic><topic>Macrophage Activation</topic><topic>Receptors, Chimeric Antigen - immunology</topic><topic>T-Lymphocytes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>McNerney, Kevin O</creatorcontrib><creatorcontrib>DiNofia, Amanda M</creatorcontrib><creatorcontrib>Teachey, David T</creatorcontrib><creatorcontrib>Grupp, Stephan A</creatorcontrib><creatorcontrib>Maude, Shannon L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Blood cancer discovery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>McNerney, Kevin O</au><au>DiNofia, Amanda M</au><au>Teachey, David T</au><au>Grupp, Stephan A</au><au>Maude, Shannon L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Potential Role of IFNγ Inhibition in Refractory Cytokine Release Syndrome Associated with CAR T-cell Therapy</atitle><jtitle>Blood cancer discovery</jtitle><addtitle>Blood Cancer Discov</addtitle><date>2022-03-01</date><risdate>2022</risdate><volume>3</volume><issue>2</issue><spage>90</spage><epage>94</epage><pages>90-94</pages><issn>2643-3230</issn><eissn>2643-3249</eissn><abstract>Here we review the pathophysiology and management of cytokine release syndrome (CRS) secondary to immunotherapy, and potential options for CRS refractory to IL6 inhibition and glucocorticoids, for which there are no proven treatments. To illustrate, we describe a patient with B-cell acute lymphoblastic leukemia who developed refractory grade 4 CRS following CD19-directed chimeric antigen receptor T-cell therapy, treated with tocilizumab, methylprednisolone, siltuximab, and the IFNγ inhibitor emapalumab, with complete remission from leukemia for 12 months. See related article by Bailey et al., p. 136 (15).</abstract><cop>United States</cop><pub>American Association for Cancer Research</pub><pmid>35015687</pmid><doi>10.1158/2643-3230.BCD-21-0203</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-4359-3569</orcidid><orcidid>https://orcid.org/0000-0002-8321-0403</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2643-3230 |
| ispartof | Blood cancer discovery, 2022-03, Vol.3 (2), p.90-94 |
| issn | 2643-3230 2643-3249 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9245357 |
| source | MEDLINE; PubMed Central |
| subjects | Cytokine Release Syndrome - drug therapy Hematologic Neoplasms Humans Immunotherapy, Adoptive - adverse effects In Focus Interferon-gamma Macrophage Activation Receptors, Chimeric Antigen - immunology T-Lymphocytes |
| title | Potential Role of IFNγ Inhibition in Refractory Cytokine Release Syndrome Associated with CAR T-cell Therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T23%3A41%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Potential%20Role%20of%20IFN%CE%B3%20Inhibition%20in%20Refractory%20Cytokine%20Release%20Syndrome%20Associated%20with%20CAR%20T-cell%20Therapy&rft.jtitle=Blood%20cancer%20discovery&rft.au=McNerney,%20Kevin%20O&rft.date=2022-03-01&rft.volume=3&rft.issue=2&rft.spage=90&rft.epage=94&rft.pages=90-94&rft.issn=2643-3230&rft.eissn=2643-3249&rft_id=info:doi/10.1158/2643-3230.BCD-21-0203&rft_dat=%3Cproquest_pubme%3E2619208974%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2619208974&rft_id=info:pmid/35015687&rfr_iscdi=true |